GlobeNewswire

ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab

Share

Regulatory progress is spurring the development of safe and effective therapies for Alzheimer’s disease

TORONTO and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, released a white paper today that offers its perspective on aducanumab’s likelihood of regulatory approval in advance of its U.S. Food and Drug Administration Advisory Committee (AC) review on November 6. The white paper, available at www.promisneurosciences.com, chronicles aducanumab’s history, regulatory support, positive data outcomes and potential impetus for development of improved second-generation therapies. If approved, aducanumab would be the first disease-modifying treatment for Alzheimer’s disease, offering a therapeutic option for the millions of Americans living with the disease.

Aducanumab was originally designed to target amyloid-beta plaque, now believed to be an ineffective drug target for AD. An accumulating body of data has shifted the drug development focus to a different species of amyloid-beta called the toxic oligomer which has since been shown to be the real culprit in driving disease progression. Aducanumab’s ability to cross-react and partially neutralize toxic oligomers results in its modest treatment benefit. By contrast, published data show that PMN310, ProMIS’ antibody candidate for Alzheimer’s disease, is highly selective for the toxic oligomer of amyloid-beta, positioning it as a second-generation drug candidate with more precise targeting capabilities and a potentially improved safety and efficacy profile.

Despite aducanumab’s modest treatment benefit, the white paper argues that FDA approval is likely based on the following:

  1. FDA has encouraged Biogen to submit its application, granting it Priority Review; has endorsed continued clinical use of aducanumab in an open-label study, and; has demonstrated a willingness in the past to approve drugs despite limited data in instances where the unmet medical need is significant.

  2. Aducanumab’s phase 3 EMERGE trial was unequivocally positive and additional evidence for effectiveness is confirmed by results from the Phase 1b PRIME trial and subset data from the phase 3 ENGAGE trial.

  3. We anticipate the Advisory Committee members will most likely conclude that aducanumab’s data demonstrate the requisite “substantial evidence of effectiveness” and acceptable safety.

“Aducanumab represents a milestone treatment, and we applaud Biogen’s unrelenting commitment to its advancement,” said Dr. Elliot Goldstein, ProMIS Neurosciences’ President and CEO. “We and many others in the Alzheimer’s community look forward to the upcoming FDA Advisory Committee meeting and subsequent regulatory actions in support of addressing the unmet need for disease modifying therapies for Alzheimer’s disease.”

The FDA’s Advisory Committee will be virtually convened and streamed via internet on November 6, 2020.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. In the infectious disease setting, these DSEs represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn. To learn more about protein misfolding diseases, listen to Episodes 11, 24, of Saving Minds, a podcast available at iTunes or Spotify.

For media inquiries, please contact:
Shanti Skiffington
shanti.skiffington@gmail.com
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Terranet etablerar leverantörskedja med Prophesee, Sensor Cortek och Summer Robotics - branschspecialister inom algoritmutveckling för bildanalys och robotautomation10.5.2021 07:00:00 CEST | Press release

Terranet har växlat upp med ett nytt tempo i produktutvecklingen av VoxelFlow genom att nyligen ha undertecknat strategiska samarbetsavtal med Prophesee, Sensor Cortek och Summer Robotics. Samtliga tre är branschspecialister inom algoritmutveckling, kamerahårdvara, robotautomation och bildanalys. Dessa ingångna samarbetsavtal tillsammans med den nyligen aviserade investeringen i Holoride (med Audi som huvudägare) samt deltagandet tidigare i år i Startup Autobahn (inkubatorn som drivs av Mercedes Benz) visar på både efterfrågan och intresset för VoxelFlowsensorn. Med ny banbrytande teknologi och potential att bli en global marknadsledare som helt förändrar spelplanen och utmanar bilindustrin är det viktigt att kontinuerligt utvärdera, identifiera och säkerställa flera kommersiella inriktningar så tidigt som möjligt. Inte minst viktigt är det att bygga upp ett ekosystem med biltillverkare och underleverantörer och att driva detta utifrån en väldefinierad roadmap, partnerskapsstrategi och

Terranet etablerar leverantörskedja med Prophesee, Sensor Cortek och Summer Robotics - branschspecialister inom algoritmutveckling för bildanalys och robotautomation10.5.2021 07:00:00 CEST | Pressemelding

Terranet har växlat upp med ett nytt tempo i produktutvecklingen av VoxelFlow genom att nyligen ha undertecknat strategiska samarbetsavtal med Prophesee, Sensor Cortek och Summer Robotics. Samtliga tre är branschspecialister inom algoritmutveckling, kamerahårdvara, robotautomation och bildanalys. Dessa ingångna samarbetsavtal tillsammans med den nyligen aviserade investeringen i Holoride (med Audi som huvudägare) samt deltagandet tidigare i år i Startup Autobahn (inkubatorn som drivs av Mercedes Benz) visar på både efterfrågan och intresset för VoxelFlowsensorn. Med ny banbrytande teknologi och potential att bli en global marknadsledare som helt förändrar spelplanen och utmanar bilindustrin är det viktigt att kontinuerligt utvärdera, identifiera och säkerställa flera kommersiella inriktningar så tidigt som möjligt. Inte minst viktigt är det att bygga upp ett ekosystem med biltillverkare och underleverantörer och att driva detta utifrån en väldefinierad roadmap, partnerskapsstrategi och

ForFarmers N.V.: Update share buy-back programme ForFarmers10.5.2021 06:55:00 CEST | Press release

Lochem, 10 May 2021 Update share buy-back programme ForFarmers ForFarmers N.V. (ForFarmers) has repurchased 68,307 shares in the period from 3 May 2021 through 7 May 2021. The shares were repurchased at an average price of €5.40 per share, for a total amount of €369,013. These repurchases were made in accordance with the authorisation granted by the ForFarmers Annual General Meeting of Shareholders on 23 April 2021 to buy back shares. This decision was published the same day, and it was announced that the share buy-back programme would start on 28 April 2021. The total number of shares that has been repurchased to date according to this programme is 101,014 shares, for a total amount of €551,684. More information about the share buy-back programme is available on the ForFarmers website www.forfarmersgroup.eu/en. This press release contains information that qualifies as inside information in the sense of Article 7 paragraph 1 of the EU Market Abuse Regulation. Download the weekly report

Novo Nordisk A/S – Share repurchase programme7.5.2021 21:31:30 CEST | Press release

Bagsværd, Denmark, 7May2021 — As part of the up to DKK 18 billion 2021 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 3.3 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). For that purpose, Novo Nordisk A/S has appointed Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, as lead manager to execute the programme independently and without influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. Under the agreement, Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting 10 May 20

Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme7.5.2021 21:24:00 CEST | Press release

Bagsværd, Denmark, 7 May2021 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2021 share repurchase programme of up to a total of DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 461.04 per share and has been calculated as the three-day volume weighted average market price from 5 May 2021 to 7 May 2021 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.5% of the share capital and 76.9% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 116,129,000 B shares of DKK 0.20, corresponding to 28.3% of the capital and 76.8% of the votes in Novo Nordisk A/S. The transaction is in line with the announcement

RomReal: Mandatory notification of insider trade - Chairman and CEO of RomReal Kjetil Gronskag7.5.2021 19:34:48 CEST | Press release

Kjetil Gronskag, Chairman and CEO of RomReal Ltd has today 07 May 2021, purchased 2000 shares of RomReal at NOK 1.74 per share in RomReal Ltd. Following this trade, Kjetil Gronskag controls privately and through holding companies 4,546,127 shares in RomReal Ltd. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

PRFOODS NOTICE OF NOTEHOLDERS’ MEETING7.5.2021 16:58:01 CEST | Press release

AS PRFoods (registry code 11560713, registered address at Pärnu mnt 141, 11314 Tallinn, Estonia; “PRFoods”) hereby notifies persons holding the notes (the “Noteholders”) of the Issuer, due on 22 January 2025 and bearing ISIN code EE3300001577 (the “Notes”), issued under the Terms and Conditions of Secured Note Issue of AS PRFoods dated 14 January 2020 (which have been amended on 25 February 2020; the “Terms”), of convening a meeting of Noteholders (the “Meeting”). The Meeting will be held on 24 May 2021 at 12:00 (EET) at Peetri 12 (Kai Kunstikeskus), 10415 Tallinn, Estonia. Registration for the Meeting will be open at the venue of the Meeting from 11:00 to 11:45 (EET). The management of PRFoods requests all Noteholders to consider that due to COVID-19 caused by the coronavirus, it is advised to minimise the extent of physical gatherings and the participation therein. For this purpose, the management of PRFoods advises to consider authorising representatives of the collateral agent to p